Survival in nephroblastoma treated according to the trial and study SIOP-9/GPOH with respect to relapse and morbidity

Weirich, A.; Ludwig, R.; Graf, Norbert; Abel, Ulrich; Leuschner, Ivo; Vujanić, Gordan; Mehls, Otto; Boos, Joachim; Jd, Beck; Royer‐Pokora, Brigitte; Voûte, P. A.

doi:10.1093/annonc/mdh171

Cited by 115 publications

(87 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Since the first SIOP protocol started in 1971, treatment intensity has been successfully reduced for the majority of patients with Wilms tumours, and survival has risen to 90% 2,[6][7][8][9][10] . Consequently, the identification of additional predictive and prognostic factors is increasingly important to improve the stratification of patients according to their individual risk.…”

Section: Treatment Recommendationsmentioning

confidence: 99%

“…Similar to the SIOP−2001 protocol, the UMBRELLA protocol continues to recommend preoperative actinomycin D and vincristine for patients newly diagnosed with Wilms tumour aged ≥6 months, based on results of previous SIOP trials that showed tumour downstaging using this regimen 2,6,8,9,14,17 . This benefit was also independently observed in the randomized, controlled UKW3 trial conducted by the UK Children's Cancer and Leukaemia Group (UKCCLG, previously known as the UK Children's Cancer Study Group) 18 .…”

Section: Treatment Recommendationsmentioning

confidence: 99%

See 1 more Smart Citation

Rationale for the treatment of Wilms tumour in the UMBRELLA SIOP–RTSG 2016 protocol

et al. 2017

View full text Add to dashboard Cite

Section: Treatment Recommendationsmentioning

confidence: 99%

Section: Treatment Recommendationsmentioning

confidence: 99%

Rationale for the treatment of Wilms tumour in the UMBRELLA SIOP–RTSG 2016 protocol

et al. 2017

View full text Add to dashboard Cite

“…Advanced clinical stage at presentation, particularly metastatic disease (stage IV), is an independent risk factor for treatment failure in Wilms' tumors (33), and local tumor spread (stage III) has been associated with a greater probability of local recurrence after treatment (34). Information concerning the clinical stage was available for 43 of the sporadic Wilms' tumors in our series.…”

Section: The Number Of Chromosomes Affected By Loh In Sporadic Wilms'mentioning

confidence: 99%

Genomic Profiling Maps Loss of Heterozygosity and Defines the Timing and Stage Dependence of Epigenetic and Genetic Events in Wilms' Tumors

Yuan

Yamashiro³

et al. 2005

Molecular Cancer Research

View full text Add to dashboard Cite

To understand genetic and epigenetic pathways in Wilms' tumors, we carried out a genome scan for loss of heterozygosity (LOH) using Affymetrix 10K single nucleotide polymorphism (SNP) chips and supplemented the data with karyotype information. To score loss of imprinting (LOI) of the IGF2 gene, we assessed DNA methylation of the H19 5V differentially methylated region (DMR). Few chromosomal regions other than band 11p13 (WT1) were lost in Wilms' tumors from Denys-Drash and Wilms' tumor-aniridia syndromes, whereas sporadic Wilms' tumors showed LOH of several regions, most frequently 11p15 but also 1p, 4q, 7p, 11q, 14q, 16q, and 17p. LOI was common in the sporadic Wilms' tumors but absent in the syndromic cases. The SNP chips identified novel centers of LOH in the sporadic tumors, including a 2.4-Mb minimal region on chromosome 4q24-q25. Losses of chromosomes 1p, 14q, 16q, and 17p were more common in tumors presenting at an advanced stage; 11p15 LOH was seen at all stages, whereas LOI was associated with early-stage presentation. Wilms' tumors with LOI often completely lacked LOH in the genome-wide analysis, and in some tumors with concomitant 16q LOH and LOI, the loss of chromosome 16q was mosaic, whereas the H19 DMR methylation was complete. These findings confirm molecular differences between sporadic and syndromic Wilms' tumors, define regions of recurrent LOH, and indicate that gain of methylation at the H19 DMR is an early event in Wilms' tumorigenesis that is independent of chromosomal losses. The data further suggest a biological difference between sporadic Wilms' tumors with and without LOI. (Mol Cancer Res 2005;3(9):493 -502)

show abstract

“…Weirich et al demonstrated that Wilms' tumor therapy should be individualized and based on the patient's age, the presence of anaplasia and the response to initial chemotherapy [8]. That analysis included 440 patients treated in accordance with the SIOP-9 protocol.…”

Section: Discussionmentioning

confidence: 99%

Clinical Factors in Relapses of Wilms’ Tumor – Results for the Polish Pediatric Solid Tumors Study Group

Niedzielska

Bronowicki²,

Pietras

et al. 2014

Adv Clin Exp Med

View full text Add to dashboard Cite

Of these 34 patients, 11 initially had CS I, seven were at CS II, four were at CS III, 11 were at CS IV and one had CS V. There were eight patients with second recurrences; of these, seven were in the INT risk group and one in the high histological risk group. There was no correlation between age (p = 0.256) or gender (p = 0.538) and the risk of tumor recurrence. In the study group, seven out of 10 patients with local recurrences are alive; as are 13 out of 22 patients with distant recurrences

show abstract

Survival in nephroblastoma treated according to the trial and study SIOP-9/GPOH with respect to relapse and morbidity

Cited by 115 publications

References 37 publications

Rationale for the treatment of Wilms tumour in the UMBRELLA SIOP–RTSG 2016 protocol

Rationale for the treatment of Wilms tumour in the UMBRELLA SIOP–RTSG 2016 protocol

Genomic Profiling Maps Loss of Heterozygosity and Defines the Timing and Stage Dependence of Epigenetic and Genetic Events in Wilms' Tumors

Clinical Factors in Relapses of Wilms’ Tumor – Results for the Polish Pediatric Solid Tumors Study Group

Contact Info

Product

Resources

About